Shares of La Jolla Pharmaceutical Co. (NASDAQ:LJPC) rose 1.9% during mid-day trading on Monday . The company traded as high as $18.87 and last traded at $18.73, with a volume of 53,557 shares trading hands. The stock had previously closed at $18.38.

LJPC has been the topic of a number of research reports. Lake Street Capital initiated coverage on shares of La Jolla Pharmaceutical in a report on Tuesday, May 24th. They issued a “buy” rating and a $25.00 price target on the stock. Jefferies Group restated a “buy” rating on shares of La Jolla Pharmaceutical in a report on Wednesday, June 8th. Zacks Investment Research downgraded shares of La Jolla Pharmaceutical from a “hold” rating to a “sell” rating in a report on Wednesday, June 15th. Finally, SunTrust Banks Inc. started coverage on shares of La Jolla Pharmaceutical in a report on Wednesday, June 22nd. They issued a “buy” rating and a $30.00 target price on the stock. Seven equities research analysts have rated the stock with a buy rating, The stock presently has an average rating of “Buy” and a consensus price target of $38.83.

The company’s 50-day moving average is $17.22 and its 200 day moving average is $17.68. The stock’s market cap is $344.27 million.

La Jolla Pharmaceutical (NASDAQ:LJPC) last announced its quarterly earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.99) by $0.09. Analysts predict that La Jolla Pharmaceutical Co. will post ($3.76) earnings per share for the current fiscal year.

La Jolla Pharmaceutical Company is a biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapies to improve outcomes in patients suffering from life-threatening diseases. It is engaged in the research, development and commercialization of its technologies and drug candidates for pharmaceutical products.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.